iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial

32 minutes ago
GlobeNewswire

For immediate release iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial Five-year safety profile…

Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer

33 minutes ago

London, UK – 24th April 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on…

Quadient Named a Leader in the SPARK Matrix™: Customer Communication Management Report for 2025

48 minutes ago

Quadient Named a Leader in the SPARK Matrix™: Customer Communication Management Report for 2025 QKS Group recognizes Quadient for its…

MYT Netherlands Parent B.V. (“Mytheresa”) and Richemont announce the successful completion of Mytheresa’s acquisition of YOOX NET-A-PORTER (“YNAP”)

58 minutes ago

MYT Netherlands Parent B.V. (“Mytheresa”) and Richemont announce the successful completion of Mytheresa’s acquisition of YOOX NET-A-PORTER (“YNAP”)   24 April 2025…

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients

1 hour ago

Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolutionRecruitment stopped early due to positive exploratory…

Tarkett Participation increases the price offered in its public buy-out Offer- Tarkett’s Supervisory Board issues a favorable reasoned opinion based on the increased Offer price and the work of the independent expert

1 hour ago

Tarkett Participation increases the price offered in its public buy-out OfferTarkett's Supervisory Board issues a favorable reasoned opinion based on…

Eramet: 2.7bn€ in economic contribution and 260,000 beneficiaries of social initiatives in the countries where it operates by 2024

2 hours ago

PRESS RELEASE Paris, April 24, 2025, 8:00 am Eramet: 2.7bn€ in economic contribution and 260,000 beneficiaries of social initiatives in the…

Pharming Group to report first quarter 2025 financial results on May 8

2 hours ago

Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited)…

Nilörn Interim Report Q1, 2025

2 hours ago

Period January - March Order intake increased by 15 percent to MSEK 267 (233)Revenue increased by 7 percent to MSEK…

Eurocastle Releases Fourth Quarter and Year End 2024 Financial Results

2 hours ago

EUROCASTLE INVESTMENT LIMITED                                  …

This website uses cookies.